Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1983 Jan;47(1):35–42. doi: 10.1038/bjc.1983.4

Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.

C H Ford, C E Newman, J R Johnson, C S Woodhouse, T A Reeder, G F Rowland, R G Simmonds
PMCID: PMC2011264  PMID: 6821632

Abstract

Safety of administration of a vindesine (VDS)-anti-CEA conjugate and its ability to localise after radiolabelling were investigated in patients with advanced metastatic carcinoma (4 colorectal and 4 ovarian). For imaging, patients received between 230 and 520 micrograms of 131I labelled antibody. In 5, localisation of conjugate was demonstrated, in another it was equivocal and in 2 patients, undetectable. For assessment of safety each patient also received a single dose of conjugate increasing from 1.2 to 42 mg antibody linked to 24 to 1800 micrograms VDS. The in vitro activity of the anti-CEA antibody and its ability to localise in vivo were preserved after conjugation. There was no obvious toxicity or hypersensitivity attributable to either the radiolocalisation or escalated doses of conjugate in any of the patients. The feasibility of the preparation and administration to patients of a vindesine-antibody conjugate has been demonstrated.

Full text

PDF
35

Images in this article

39Figure 1
on p.39
39Figure 2
on p.39

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Booth S. N., King J. P., Leonard J. C., Dykes P. W. Serum carcinoembryonic antigen in clinical disorders. Gut. 1973 Oct;14(10):794–799. doi: 10.1136/gut.14.10.794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cobleigh M. A., Williams S. D., Einhorn L. H. Phase II study of vindesine in patients with metastatic breast cancer. Cancer Treat Rep. 1981 Jul-Aug;65(7-8):659–663. [PubMed] [Google Scholar]
  3. Conrad R. A., Cullinan G. J., Gerzon K., Poore G. A. Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates. J Med Chem. 1979 Apr;22(4):391–400. doi: 10.1021/jm00190a008. [DOI] [PubMed] [Google Scholar]
  4. Davies D. A., O'Neill G. J. In vivo and in vitro effects of tumour specific antibodies with chlorambucil. Br J Cancer Suppl. 1973 Aug;1:285–298. [PMC free article] [PubMed] [Google Scholar]
  5. Dykes P. W., Hine K. R., Bradwell A. R., Blackburn J. C., Reeder T. A., Drolc Z., Booth S. N. Localisation of tumour deposits by external scanning after injection of radiolabelled anti-carcinoembryonic antigen. Br Med J. 1980 Jan 26;280(6209):220–222. doi: 10.1136/bmj.280.6209.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ford C. H., Stokes H. J., Newman C. E. Carcinoembryonic antigen and prognosis after radical surgery for lung cancer: immunocytochemical localization and serum levels. Br J Cancer. 1981 Aug;44(2):145–153. doi: 10.1038/bjc.1981.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ghose T., Blair A. H. Antibody-linked cytotoxic agents in the treatment of cancer: current status and future prospects. J Natl Cancer Inst. 1978 Sep;61(3):657–676. [PubMed] [Google Scholar]
  8. Ghose T., Norvell S. T., Guclu A., Cameron D., Bodurtha A., MacDonald A. S. Immunochemotherapy of cancer with chlorambucil-carrying antibody. Br Med J. 1972 Aug 26;3(5825):495–499. doi: 10.1136/bmj.3.5825.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goldenberg D. M., Sharkey R. M., Primus F. J. Immunocytochemical detection of carcinoembryonic antigen in conventional histopathology specimens. Cancer. 1978 Sep;42(3 Suppl):1546–1553. doi: 10.1002/1097-0142(197809)42:3+<1546::aid-cncr2820420829>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  10. Johnson J. R., Ford C. H., Newman C. E., Woodhouse C. S., Rowland G. F., Simmonds R. G. A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro. Br J Cancer. 1981 Sep;44(3):472–475. doi: 10.1038/bjc.1981.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lee F. H., Hwang K. M. Antibodies as specific carriers for chemotherapeutic agents. Cancer Chemother Pharmacol. 1979;3(1):17–24. doi: 10.1007/BF00254415. [DOI] [PubMed] [Google Scholar]
  12. MATHE G., TRAN BA L. O. C., BERNARD J. Effet sur la leucémie 1210 de la souris d'un combinaison par diazotation d'A-méthoptèrine et de gamma-globulines de hamsters porteurs de cette leucèmie par hétérogreffe. C R Hebd Seances Acad Sci. 1958 Mar 10;246(10):1626–1628. [PubMed] [Google Scholar]
  13. Miller R. A., Levy R. Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet. 1981 Aug 1;2(8240):226–230. doi: 10.1016/s0140-6736(81)90475-x. [DOI] [PubMed] [Google Scholar]
  14. Nadler L. M., Stashenko P., Hardy R., Kaplan W. D., Button L. N., Kufe D. W., Antman K. H., Schlossman S. F. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980 Sep;40(9):3147–3154. [PubMed] [Google Scholar]
  15. Newman C. E., Ford C. H. Antibody-drug synergism: An assessment of specific passive immunotherapy in bronchial carcinoma. Lancet. 1977 Jul 23;2(8030):163–166. doi: 10.1016/s0140-6736(77)90180-5. [DOI] [PubMed] [Google Scholar]
  16. Osterlind K., Dombernowsky P., Sørensen P. G., Hansen H. H. Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma. Cancer Treat Rep. 1981 Mar-Apr;65(3-4):245–248. [PubMed] [Google Scholar]
  17. Valdivieso M., Bedikian A. Y., Bodey G. P., Freireich E. J. Broad phase II study of vindesine. Cancer Treat Rep. 1981 Sep-Oct;65(9-10):877–879. [PubMed] [Google Scholar]
  18. Valdivieso M., Richman S., Burgess A. M., Bodey G. P., Freireich E. J. Initial clinical studies of vindesine. Cancer Treat Rep. 1981 Sep-Oct;65(9-10):873–875. [PubMed] [Google Scholar]
  19. Yap H. Y., Blumenschein G. R., Bodey G. P., Hortobagyi G. N., Buzdar A. U., DiStefano A. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep. 1981 Sep-Oct;65(9-10):775–779. [PubMed] [Google Scholar]
  20. van Nagell J. R., Jr, Donaldson E. S., Gay E. C., Hudson S., Sharkey R. M., Primus F. J., Powell D. F., Goldenberg D. M. Carcinoembryonic antigen in carcinoma of the uterine cervix. 2. Tissue localization and correlation with plasma antigen concentration. Cancer. 1979 Sep;44(3):944–948. doi: 10.1002/1097-0142(197909)44:3<944::aid-cncr2820440323>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  21. van Nagell J. R., Jr, Kim E., Casper S., Primus F. J., Bennett S., DeLand F. H., Goldenberg D. M. Radioimmunodetection of primary and metastatic ovarian cancer using radiolabeled antibodies to carcinoembryonic antigen. Cancer Res. 1980 Mar;40(3):502–506. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES